The Recall Desk
Agency classClass IIOur severity:ModerateFDA (Drugs)·D-1274-2015·Announced 2015-07-29

Wockhardt Recalls Zonisamide Capsules Due to Inadequate Complaint Investigation

Wockhardt USA is recalling Zonisamide Capsules, 25 mg, because the firm did not adequately investigate customer complaints.

The agency’s classification

FDA (Drugs): Class II

Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.

This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work

What this means for you

Our assessment, not the agency’s: severity 2/5 (Moderate).

Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.

Our severity reasoning: The recall is classified as FDA Class II, which is a moderate risk. The source text cites a procedural CGMP deviation (inadequate complaint investigation) without reporting specific injuries, illnesses, or deaths, fitting the criteria for a moderate severity score.

Plain-English summary

Wockhardt USA LLC is recalling Zonisamide Capsules, 25 mg, packaged in 100-count bottles. The product is prescription-only and was manufactured by Wockhardt Limited in Mumbai, India. The recall involves 68,066 bottles distributed nationwide in the U.S., including Puerto Rico.

The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations. Specifically, the firm did not adequately investigate customer complaints. The affected lots have expiration dates ranging from April 30, 2015, to April 30, 2016.

Consumers with this medication should contact their healthcare provider or pharmacist for guidance on how to proceed. The specific lot numbers and expiration dates are listed in the official recall notice.

The recalled product

Product
Zonisamide Capsules, 25 mg Capsules, Packaged in 100 Count Bottles, Rx Only. Manufactured by: Wockhardt Limited, Mumbai, India. Distributed by: Wockhardt USA LLC 20 Waterview Blvd. Parsippany, NJ 07054 USA. NDC: 64679-0945-01.
Manufacturer
Wockhardt Usa Inc.
Category
Drug — Anticonvulsant
Hazard
Affected units
68,066

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (20)

  • Lot #: LM10763
  • Expiry: 4/30/2015
  • Lot #: LM10764
  • Lot #: LM10765
  • Lot #: LM11142
  • Expiry: 6/30/2015
  • Lot #: LM11143
  • Lot #: LM11144
  • Lot #: LM11255
  • Expiry: 7/31/2015
  • Lot #: LM11256
  • Lot #: LM11265
  • Lot #: LM11542
  • Expiry: 8/31/2015
  • Lot #: LM11543
  • Lot #: LN10197
  • Expiry: 12/31/2015
  • Lot #: LN10198
  • Lot #: LN10199
  • Lot #: LN10200

Distribution

Distributed nationwide across the United States.

The notice also names 1 state specifically:

Part of a larger recall action

This product is one of 35 recalled by Wockhardt Usa Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.

See all 35 products in this recall →

Related recalls

Same manufacturer · Wockhardt Usa Inc.

See all →

Same hazard · cgmp deviation

See all →

Similar recalls